bioRxiv · 10.1101/2023.03.17.533120
Harnessing PROTAC technology to combat stress hormone receptor activation
Abstract
Counteracting the overactivation of glucocorticoid receptors (GR) is an important therapeutic goal in stress-related psychiatry and beyond. The only clinically approved GR antagonist lacks selectivity and induces unwanted side effects. To complement existing tools of small-molecule-based inhibitors, we present a highly potent, novel catalytically-driven GR degrader, KH-103, based on proteolysis-targeting chimera technology. This selective degrader enables immediate and reversible GR depletion that is independent of genetic manipulation and circumvents transcriptional adaptations to inhibition. KH-103 achieves passive inhibition, preventing agonistic induction of gene expression, and significantly averts the GRs genomic effects compared to two currently available inhibitors. Application in primary-neuron cultures revealed the dependency of a glucocorticoid-induced increase in spontaneous calcium activity on GR. Finally, we present a proof of concept for application in-vivo. KH-103 opens opportunities for a more lucid interpretation of GR functions with translational potential.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Gazorpak, M., Hungentobler, K. M., Dominique, P., Germain, P.-L., Mathis, K., Rudolf, R., Barrenechea, S. M., Kretschmer, M., Fischer, V. V., Xue, X., Privitera, M., Ivanova, I., Hierlemann, A., Meijer, O. C., Carreira, E. M., Bohacek, J., Gapp, K.. 2023-03-18. Harnessing PROTAC technology to combat stress hormone receptor activation. https://doi.org/10.1101/2023.03.17.533120
Cite the original work for its findings. Save a collection to share your selection of sources.